Tdam USA Inc. lowered its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 6.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,468 shares of the medical instruments supplier’s stock after selling 170 shares during the period. Tdam USA Inc.’s holdings in C.R. Bard were worth $777,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. SRS Capital Advisors Inc. raised its position in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the last quarter. Creative Planning raised its position in shares of C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares during the last quarter. Blair William & Co. IL raised its position in shares of C.R. Bard by 0.9% in the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock valued at $865,000 after buying an additional 30 shares during the last quarter. First Merchants Corp raised its position in shares of C.R. Bard by 0.6% in the second quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock valued at $1,623,000 after buying an additional 32 shares during the last quarter. Finally, Pennsylvania Trust Co raised its position in shares of C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 35 shares during the last quarter. 85.32% of the stock is currently owned by hedge funds and other institutional investors.
Shares of C.R. Bard, Inc. (BCR) opened at 318.18 on Wednesday. The firm has a 50 day moving average price of $318.45 and a 200-day moving average price of $280.37. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The company has a market cap of $23.12 billion, a P/E ratio of 41.77 and a beta of 0.59.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same quarter in the previous year, the company posted $2.54 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. Analysts anticipate that C.R. Bard, Inc. will post $11.83 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were issued a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio is presently 13.67%.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/08/09/c-r-bard-inc-bcr-position-cut-by-tdam-usa-inc.html.
Several brokerages have weighed in on BCR. BidaskClub lowered C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday. Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. C.R. Bard has a consensus rating of “Hold” and an average price target of $285.67.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
